The global obesity treatment market size valued US$ 752.6 million in 2020 and expected to reach US$ 1,078.9 million by 2027, at a CAGR of 16.7% during forecast period 2021-2027. Obesity is the medical condition occurs due to the excessive or abnormal accumulation of fat inside the body. Obesity is measured with respect to Basal Metabolic Index (BMI). According to world health organization, more than 30 BMI is considered as the obese. Obesity may lead to osteoarthritis, cardiovascular diseases, diabetes, and various types of cancer. The risk factors for obesity include lack of physical exercise, excessive food intake, endocrine disorders, genetic inheritance, and due to some medications. obesity treatment reduces the body mass either by an increase in calorie consumption or by the decrease in craving. Global Obesity Treatment Market expected to grow at a significant CAGR owing to increase in the R&D activities for the innovation of new products and presence of various pipeline products for the treatment of obesity. Increase in the prevalence of obese population fuelling the obesity treatment market growth. According to World Health Organization 2014, more than 39% of adults (600 Mn adults) adults and 42 Mn children were obese. In addition, entry of generic products due to patent expiry of blockbuster treatment also driving the revenue of obesity treatment. For instance, in March 2017, Novo Nordisk has received European Commission marketing authorization approval of Saxenda an injectable obesity drug and launched the same in India market in 2017.